About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More

NCT01237067

Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers

Study identifier: NCT01237067
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Olaparib (AstraZeneca)

Eligibility:

  • Patients must have confirmed at the NCI, histologically or cytologically recurrent/refractory epithelial ovarian, fallopian, primary peritoneal, uterine papillary serous cancer, or malignant mixed mullerian tumor.
  • All patients must have measurable and/or evaluable disease; biomarker-only disease is not considered measurable or evaluable.
  • Ovarian or endometrial cancer patients with deleterious mutation in DNA repair enzymes may be treated in first recurrence independent of platinum-sensitivity history.
  • Patients must be at least 6 months from their last platinum exposure and platinum-resistant patients may participate.

Type of study:

Phase I study

Treatment:

Patients who enroll will receive olaparib plus carboplatin.

Study site:

Maryland

National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
Contact: Laura D.Otten, R.N., B.S.N., O.C.N.
Medical Oncology Referral Coordinator 301-451-1228
1-866-611-6310 (Toll Free) ottenl@mail.nih.gov

 

Page updated 03/26/11

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us

Morphtek

This site has been made possible by a generous grant from Morphotek.


Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org